Navigation Links
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
Date:12/2/2009

NEW YORK, Dec. 2 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of relapsed/refractory multiple myeloma.

The Fast Track program of the FDA is designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Fast Track designated drugs ordinarily qualify for priority review, thereby expediting the FDA review process.

A Phase 3 trial investigating perifosine in combination with bortezomib (VELCADE®) and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma is expected to commence by year-end under a Special Protocol Assessment (SPA) with the FDA. In addition, in September, the Company announced that perifosine had received Orphan-Drug designation in the United States for the treatment of multiple myeloma.

Ron Bentsur, Chief Executive Officer of Keryx Biopharmaceuticals, commented, "This Fast Track designation can significantly reduce the FDA review time of a new drug application, and therefore can expedite the time to market for perifosine in multiple myeloma." Mr. Bentsur added, "We believe that the Fast Track designation, together with the SPA and Orphan Drug status previously granted to us by the FDA for perifosine in multiple myeloma, significantly enhances the value proposition of perifosine in this indication. We are eager to begin the Phase 3 trial later this month."

KRX-0401 (perifosine) is in-licensed by
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
2. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
3. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
6. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
7. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
8. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
9. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
10. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... DIEGO, Oct. 31, 2014 Mast Therapeutics, Inc. ... financial results for the quarter ended September 30, 2014. ... Executive Officer, said:  "The third quarter was productive for ... study of MST-188 for sickle cell disease is on ... year. We now have opened 50 study sites in the ...
(Date:10/31/2014)... , October 31, 2014 ... Corporation (NASDAQ: CELG ), Bristol-Myers Squibb Co. ... UNH ), Sanofi SA (NYSE: ... members receive these notes ahead of publication. To reserve ... . , ,-- ,Celgene Corporation Research Reports ,On October ...
(Date:10/31/2014)... -- Encision Inc. (OTCQB:ECIA), a medical device company owning patented ... minimally invasive surgery, today announced financial results for its ... The Company posted quarterly net revenue of $2.279 ... or $(0.04) per share. These results compare to net ... $50 thousand, or $(0.01) per share, in the year-ago ...
Breaking Medicine Technology:Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 4Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 5Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 6Encision Reports Second Quarter Fiscal Year 2015 Results 2Encision Reports Second Quarter Fiscal Year 2015 Results 3Encision Reports Second Quarter Fiscal Year 2015 Results 4Encision Reports Second Quarter Fiscal Year 2015 Results 5
... DURHAM, N.C.--(BUSINESS WIRE)--Jul 3, 2007 - Inspire,Pharmaceuticals, Inc. ... and CEO, will present at the C.E.,Unterberg, Towbin ... at 11:00 am ET in New York City., ... on Inspire's,web site at www.inspirepharm.com. An archived version ...
... 28, 2007 /PRNewswire-FirstCall/ -- Auxilium,Pharmaceuticals, Inc. today announced ... and Mr. Jim Fickenscher, Chief,Financial Officer, will participate ... be held July 10 through July 12,2007 at ... Mr. Anido is,scheduled to present an overview of ...
Cached Medicine Technology:Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging,Growth Opportunities Conference 2Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging,Growth Opportunities Conference 3
(Date:11/1/2014)... 01, 2014 Almost half of the country’s ... situation according to a study done by Recorded Future, as ... October 29th. For a little over 9 months, ... how prominent the problem of exposed employee credentials really is ... eye-opening numbers. They determined 221 Fortune 500 companies had employees ...
(Date:11/1/2014)... leading online merchant, TheBeautyPlace.com announced today that a new website ... a website redesign, a sophisticated, clean look, and a new ... an easy online shopping experience. , “We recognized that it ... wayside in e-commerce. With the everlasting presence of mobile technology ... site to our new desktop site will allow us to ...
(Date:11/1/2014)... Tara Haelle HealthDay Reporter ... can both sense adult anger and alter their behavior in ... sponges," said study co-author Andrew Meltzoff, co-director of the University ... "They learn not only from their own direct social experiences ... He said he was most surprised at how emotionally ...
(Date:10/31/2014)... of cell division is central to life. The last ... has fascinated scientists since the dawn of cell biology ... has been notoriously difficult to study this final step, ... in two. , The name given to this process ... and captures the sense of a highly active and ...
(Date:10/31/2014)... 31, 2014 — A team from the Broad ... University of California, Santa Cruz, was awarded one ... Cloud Pilot contracts with the goal of building ... The Cancer Genome Atlas (TCGA) and other datasets ... resources in one cloud environment. This co-location will ...
Breaking Medicine News(10 mins):Health News:Third Party Hacks Can Pose Significant Threat to Businesses, Just Look at the Fortune 500 2Health News:Third Party Hacks Can Pose Significant Threat to Businesses, Just Look at the Fortune 500 3Health News:Third Party Hacks Can Pose Significant Threat to Businesses, Just Look at the Fortune 500 4Health News:Third Party Hacks Can Pose Significant Threat to Businesses, Just Look at the Fortune 500 5Health News:TheBeautyPlace.com to Re-launch Website with New Design and Features 2Health News:Study Shows How Toddlers Adjust to Adult Anger 2Health News:Study Shows How Toddlers Adjust to Adult Anger 3Health News:Cell division, minus the cells 2Health News:Cell division, minus the cells 3Health News:Broad Institute, Univ. of California team awarded NCI Cancer Genomics Cloud Pilot contract 2Health News:Broad Institute, Univ. of California team awarded NCI Cancer Genomics Cloud Pilot contract 3
... WASHINGTON, Nov. 2 Over the last few months, ... incorrectly aimed by a few in Congress toward physician ... uncovered the real problem - large, corporate hospitals who ... Last week, the Department of Justice (DOJ) announced that ...
... Stereotactic body radiation therapy (SBRT) stopped the growth of cancer ... among nearly 98 percent of patients with early non-small cell ... surgically removed, according to an updated three-year study presented November ... Society for Radiation Oncology (ASTRO). , The study also shows ...
... Another large community H1N1 influenza clinic has been scheduled ... It will be held at Freedom Hill County Park in ... 3 p.m. Freedom Hill is located at 14900 Metropolitan Parkway. ... community clinics at Freedom Hill, Wednesday through Saturday. A total ...
... NASHVILLE, Tenn., Nov. 2 Brookdale Senior Living Inc. (NYSE: ... results for the third quarter of 2009. , ... strong results this quarter which build on the success of ... is operating effectively in today,s difficult environment as evidenced by ...
... Ill., Nov. 2 Accelify announced today that Indian Prairie ... Medicaid claiming services. Indian Prairie School District serves 28,825 ... State of Illinois. , "We are privileged to have ... its outstanding administrative team," said Alex Brecher, COO of Accelify. ...
... of BPA Were Detected in Some Samples of Green Beans and ... to Cause Harm in Animal Studies; FDA,s Safety Standards for BPA ... Consumer Reports, latest tests of canned foods, including soups, juice, ... 19 name-brand foods tested contain measurable levels of Bisphenol A (BPA). ...
Cached Medicine News:Health News:US Department of Justice Confirms Large Corporate Owned Hospitals Involved in Illegal Contracting Schemes in McAllen Texas, Not Physician Owned Hospitals 2Health News:Stereotactic Radiotherapy Stops Lung Cancer From Growing in Frail Patients 2Health News:Macomb County Announces Another H1N1 Flu Vaccine Clinic Saturday, Nov. 7; Both Types of Vaccine Available for Free 2Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 2Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 3Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 4Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 5Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 6Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 7Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 8Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 9Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 10Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 11Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 12Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 13Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 14Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 15Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 16Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 17Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 18Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 19Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 20Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 21Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 22Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 23Health News:Indian Prairie School District Awards Contract to Accelify 2Health News:Consumer Reports: Tests Find Wide Range of Bisphenol A in Canned Soups, Juice, and More 2Health News:Consumer Reports: Tests Find Wide Range of Bisphenol A in Canned Soups, Juice, and More 3Health News:Consumer Reports: Tests Find Wide Range of Bisphenol A in Canned Soups, Juice, and More 4Health News:Consumer Reports: Tests Find Wide Range of Bisphenol A in Canned Soups, Juice, and More 5
Suture scissor...
Threaded cannula for use with Suretac® II, sterile packs, box of 10....
The Small Oval Cannula System is designed to be the smallest oval cannula system currently available, and is utilized with the Caspari Suture Punch System. Disposable seals are available with this sy...
... is for arthroscopic and open soft tissue repair ... procedural steps. It may be used with ... in conjunction with,anchors or screws (including suture pre-assembled ... tip permits the placement of a variety of ...
Medicine Products: